Usage and dosage of Secukinumab

The recommended dose of secukinumab in adults with plaque psoriasis is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Each 300 mg dose is given as one subcutaneous injection of 300 mg or two subcutaneous injections of 150 mg. For some patients, a dose of 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter may be acceptable. In pediatric patients 6 years of age and older with plaque psoriasis, the recommended weight-based dosage is administered by subcutaneous injection at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. The recommended dose for patients weighing <50 kg (at time of administration) is 75 mg, and for patients ≥50 kg (at time of administration), the recommended dose is 150 kg.

The recommended dose of secukinumab for adults with psoriatic arthritis (PsA) and moderate to severe plaque psoriasis is 300 mg, an injectable dose similar to that for plaque psoriasis. For other adult patients with PsA, secukinumab may be administered by subcutaneous injection with or without a loading dose of 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter, and a no-loading dose of 150 mg every 4 weeks. If the patient continues to have active PsA, consider a dose of 300 mg subcutaneously every 4 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or two subcutaneous injections of 150 mg.

Administer the recommended weight-based dose by subcutaneous injection to pediatric patients 2 years and older with PsA at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. The recommended dose for patients ≥15kg and <50kg is 75mg, and for patients ≥50kg the recommended dose is 150mg. Can be used in combination with methotrexate or alone.

For adult patients with Ankylosing Spondylitis (AS), Nonradiographic axial spondyloarthritis (nr-axSpA) the loading dose is 150 mg at weeks 0, 1, 2, 3 and 4 and every 4 weeks thereafter, and the no-loading dose is 150 mg every 4 weeks. If the patient continues to have active AS, consider subcutaneous injection of 300 mg every 4 weeks. The recommended body weight dose for pediatric patients 4 years and older with Enthesitis-associated arthritis (ERA) ERA, administered by subcutaneous injection at weeks 0, 1, 2, 3 and 4 and every 4 weeks thereafter, is 75 mg for patients ≥15 kg and <50 kg and 150 mg for patients ≥50 kg.

SecukinumabThe original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. SpecificationsThe price of each box of 150mg/ML is around RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.